UNSPSC 51371703: Narceine hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C23H27NO8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B7W51YUQ3, chemically known as 2,3-dimethoxy-6-((6-(2-dimethylaminoethyl)-2-methoxy-3,4-methylendioxyphenyl)acetyl)benzosaeure hydrochlorid but more generally known as narceine hydrochloride, which bears US NIH Compound Identifier 78617. Most nations, for tariff and trade purposes, schedule narceine hydrochloride under HS 29391900 and SITC 54141.

As of Q4 2014, NARCEINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Narceine hydrochloride bears US NLM identifiers UMLS ID C2828281 and NCI Concept Code C87363. SMILES: CN(C)CCC1CC2C(C(C1CC(=O)C3CCC(C(C3C(=O)O)OC)OC)OC)OCO2.CL.

UNSPSC 51371703 Narceine hydrochloride is a Commodity code nominally describing a single pharmaceutical product, but recent state and local solicitation activity shows misalignment between the code's title and the work actually being procured. The recent opportunities tagged under this code involve procurement of naloxone, prescription drug programs, and multi-source generic pharmaceuticals and over-the-counter products rather than narceine hydrochloride specifically. State and local governments buying under this code are sourcing pharmaceutical products and drug-related services through health departments, cooperative purchasing alliances, and state health agencies. Issuing bodies include county health authorities (Seminole County, Florida), state health commissions (Texas HHS), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The scope reflects procurement of pharmaceuticals, drug deactivation systems, and pharmacy benefit program management services to support public health initiatives and employee health plans.

Geographic activity spans Florida, Texas, and Minnesota, with MMCAP's cooperative purchasing vehicle extending to Oregon and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Seminole County Community Health Building; Texas HHS's RFI HHS0017013 (posted April 3, 2026) requesting vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels; and MMCAP's S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic multi-source pharmaceuticals and OTC products with requirements for cGMP and Drug Supply Chain Security Act compliance, authorized-wholesaler relationships, and pricing flexibility through multiple net-price formats. The code shows active state and local pharmaceutical procurement but exhibits significant tagging misalignment with its nominal product name.